Sugi Predict

Sugi Predict / Compounds / SCHEMBL4592621

SCHEMBL4592621

SCHEMBL4592621

CSc1ccc(-c2cc(-c3ccncc3)n(-c3ccc(F)cc3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 7/20 0.52
▸ MAPK14 Q16539 8/20 0.51
▸ MAPK13 O15264 6/20 0.51
▸ MAPK12 P53778 6/20 0.51
▸ MAPK11 Q15759 6/20 0.51
▸ GCGR P47871 7/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ FLT3 P36888 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ PRKD3 O94806 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ RET P07949 1/20 0.44
▸ ALOX5 P09917 1/20 0.44
▸ PRKACA P17612 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6525798 0.84 MAPK13 (0.48) PTGS2MAPK14MAPK13MAPK12MAPK11
SCHEMBL4592993 0.83 MEN1 (0.57) PTGS2MAPK14MAPK13MAPK12MAPK11
SCHEMBL9207835 0.81 PTGS2 (0.51) PTGS2MAPK14MAPK13MAPK12MAPK11
SCHEMBL4593759 0.81 PTGS2 (0.79) PTGS2PTGS1ALOX5
SCHEMBL4592735 0.81 PTGS2 (0.53) PTGS2MEN1NPC1LMNARAB9A
SCHEMBL6780629 0.80 PTGS2 (0.49) PTGS2MAPK14MAPK13MAPK12MAPK11
SCHEMBL6780624 0.80 PTGS2 (0.49) PTGS2MEN1NPC1LMNARAB9A
SCHEMBL9202494 0.79 PTGS2 (0.52) PTGS2MAPK14MAPK13MAPK12MAPK11
SCHEMBL9206412 0.79 PTGS2 (0.49) PTGS2MAPK14MAPK13MAPK12MAPK11
SCHEMBL9207930 0.79 PTGS2 (0.43) PTGS2MEN1NPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153569-A1 Novel pyrazole and pyrazoline substituted compounds SMITHKLINE BEECHAM CORPORATION 2003-08-14 — — US claimed
US-20020156104-A1 CSBP/p38/RK kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-24 — — US claimed
EP-1023066-A4 NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2001-05-23 — — EP claimed
EP-1023066-A1 NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-08-02 — — EP claimed
WO-1998056377-A1 NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1998-12-17 — — WO claimed
EP-1539121-A4 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2008-08-13 — — EP disclosed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
EP-1583535-A4 METHODS FOR TREATING DIABETES SCIOS INC (US) 2008-03-19 — — EP disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 — — US disclosed
US-20040162289-A1 Methods of promoting osteogenesis UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY 2004-08-19 — — US disclosed
US-6774127-B2 TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2004-08-10 — — US disclosed
WO-2004019873-A9 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2004-06-24 — — WO disclosed
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase SCIOS, INC. 2004-06-24 — — US disclosed
WO-2004053107-A2 METHODS FOR TREATING DIABETES SCIOS INC. (US) 2004-06-24 — — WO disclosed
WO-2004019873-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2004-03-11 — — WO disclosed
US-20020156104-A1 CSBP/p38/RK kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 PTGS2 919/4885MAPK14 23/4885MAPK13 15/4885
US-20040162289-A1 Methods of promoting osteogenesis MAPK1, BMP2, MAPK3 PTGS2 919/4885MAPK14 23/4885MAPK13 15/4885
US-20030153569-A1 Novel pyrazole and pyrazoline substituted compounds PDXK, COQ8A, PDK3 PTGS2 3455/4885MAPK14 578/4885MAPK13 719/4885
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase OPRK1, OPRL1, MAPK3 PTGS2 70/4885MAPK14 36/4885MAPK13 39/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 PTGS2 70/4885MAPK14 36/4885MAPK13 39/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 PTGS2 315/4885MAPK14 53/4885MAPK13 46/4885
US-20020156104-A1 CSBP/p38/RK kinase inhibitors MAPKAPK2, MAPKAPK3, MAPKAPK5 PTGS2 2606/4885MAPK14 35/4885MAPK13 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.